Azimut Exploration Inc. press release
Today's Research Reports on Aptose Biosciences, ProMIS Neurosciences, Emblem and BELLUS Health
TSXV - TSX Venture Exchange · Gold · Silver · Copper · Zinc · Antimony · Lithium · Cesium · Rubidium · Gallium · Tin · Nickel · Platinum · Palladium · Platinum Group Metals · Cobalt · Molybdenum · Rare Earth Elements · Tungsten · Canada
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.comand get exclusive access to our numerous research reports and market updates.
The Market Edge Initiates Coverage on:
Aptose Biosciences Inc. https://marketedgereport.com/report/APS.TO/
ProMIS Neurosciences, Inc. https://marketedgereport.com/report/PMN.TO/
Emblem Corp. https://marketedgereport.com/report/EMC.V/
BELLUS Health Inc. https://marketedgereport.com/report/BLU.TO/
Aptose Biosciences' stock moved 2.66% lower Monday, to close the day at $2.93. The stock recorded a trading volume of 48,720 shares, which was above its three months average volume of 41,770 shares. In the last year, Aptose Biosciences' shares have traded in a range of 2.18 - 5.97. The share price has gained 34.4% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.93 is lower than its 200-day moving average of $3.73. Shares of Aptose Biosciences have gained approximately 5.4 percent year-to-date.
Access The Market Edge's Aptose Biosciences Inc. Research Report: https://marketedgereport.com/report/APS.TO/
On Monday, shares of ProMIS Neurosciences recorded a trading volume of 44,680 shares, which was below the three months average volume of 188,835 shares. The stock ended the day 4.65% higher at $0.225. The share price has fallen 69.18% from its 52 week high with a 52 week trading range of 0.19 - 0.73. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.243 is lower than its 200-day moving average of $0.309. Shares of ProMIS Neurosciences have gained approximately 15 percent year-to-date.
Access The Market Edge's ProMIS Neurosciences, Inc. Research Report: https://marketedgereport.com/report/PMN.TO/
Emblem's stock had no change Monday, to close the day at $1.00. The stock recorded a trading volume of 791,883 shares, which was above its three months average volume of 694,159 shares. In the last year, Emblem's shares have traded in a range of 0.83 - 2.76. The share price has gained 20.48% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.19 is lower than its 200-day moving average of $1.36. Shares of Emblem have fallen approximately 56.14 percent year-to-date.
Access The Market Edge's Emblem Corp. Research Report: https://marketedgereport.com/report/EMC.V/
On Monday, shares of BELLUS Health recorded a trading volume of 1,632,618 shares, which was above the three months average volume of 235,942 shares. The stock ended the day 12.17% higher at $1.29. The share price has fallen 0.77% from its 52 week high with a 52 week trading range of 0.33 - 1.30. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.97 is greater than its 200-day moving average of $0.82. Shares of BELLUS Health have gained approximately 248.65 percent year-to-date.
Access The Market Edge's BELLUS Health Inc. Research Report: https://marketedgereport.com/report/BLU.TO/
Our Actionable Research on Aptose Biosciences Inc. (TSX:APS.TO), ProMIS Neurosciences, Inc. (TSX:PMN.TO), Emblem Corp. (TSXV:EMC.V) and BELLUS Health Inc. (TSX:BLU.TO) can be downloaded free of charge at The Market Edge.
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
contact@marketedgereport.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: MarketEdgeReport